Hydrix Limited · ASX:HYD
Hydrix — Shareholder Meeting (November 2022)
18 slides from Hydrix's shareholder meeting presentation, Nov 30, 2022
Slide 1: Annual General Meeting 2022
Annual General Meeting 2022
Slide 2: Momentum is Building
For personal use only Momentum is Building Hydrix Services: • 40% FY22 YoY revenue growth • Strong growth and profitability ahead Hydrix Ventures: • 35% YoY increase in portfolio book value to $3.65m • Major valuation inflection points anticipated Hydrix Medical: • First product the GUARDIAN, is a m
Slide 3: Hydrix Services FY22 results
For personal use only • 40% YoY revenue growth to $10.3m ($7.35m FY21) • >50% of revenues from outside Australia • >40% from clients developing emerging cardiovascular technologies • 55 employees – very high employee engagement survey results • +20% YoY trend revenue growth, 1Q23 was +23% pcp • Ente
Slide 4: Hydrix Services international growth
For personal use only • Strong focus on growing international medtech clients in the A$2B outsourced product development market • Since COVID, have appointed business development managers in Europe and recently the USA • Client facing engagement increasing sales conversion rates, and attendance at k
Slide 5: Hydrix Ventures portfolio progress
For personal use only • Gyder Surgical o Hydrix completed 1st generation commercial product • Angel Medical o Commenced ‘controlled market launch’ +100 implants completed o Positively, is achieving high re-order rates within controlled launch sites, a leading metric of market potential o US public h
Slide 6: The Guardian heart attack alert device
For personal use only • The Guardian is the worlds first and only real-time heart attack alert device, more reliable than patient symptoms alone • It can detect silent or asymptomatic heart attacks (almost half of patient events) • If 2%-5% capture rate & pending A$10k/device selling direct into ini
Slide 7: Guardian regulatory and market development plans
For personal use only • Singapore regulatory approval received August 2022 o Major Guardian launch in Singapore at December cardiology conference to drive Asia cardiologist and patient awareness o Media outlets publishing editorials o Apply for inclusion on Table of Surgical Procedures (next listing
Slide 8: Corporate and investor engagement highlights
For personal use only • Featured in and/or presented to more than 18 financial editorial pieces and news networks • Presented at Australian Microcap Investment Conference • Released Fresh Amplify “The Chairman’s List” Podcast Spotify • Quarterly shareholder newsletters • Established Hydrix Interacti
Slide 9: Momentum ahead by division
For personal use only Hydrix Services: Strong growth and profitability ahead Hydrix Services: Strong year-on-year growth, profitability ahead Hydrix Ventures: Hydrix Ventures: Major valuation inflection points ahead Major valuation inflection points anticipated in CY23 Hydrix Medical: Hydrix Medical
Slide 10: Appendix
10 | For personal use only Appendix
Slide 11: Major shareholders and capital structure
For personal use only Major Shareholders Shares (m) % Capital Structure (as of 28 November 2022) John W. King & related entities 27.3 10.8 Ticker HYD Paul Lewis & related entities 14.9 5.9 Share Price $0.055 Pusen Medical Technology Australia Pty Ltd 11.1 4.4 Shares on Issue (m) 252.5 Roger Allen &
Slide 12: Hydrix vision and commercial model
For personal use only Hydrix Medical Hydrix Ventures Distribute Bring to disruptive market disruptive Invest in early stage, high cardiovascular cardiovascular products potential, medical device Our vision is to thatproducts to solve solve unmet needs clients unmet needs improve a billion lives Our
Slide 13: Hydrix Ventures investments
For personal use only Angel Medical Gyder Surgical Cyban Memphasys Systems, USA Limited Limited Limited Manufacturer of The GUARDIAN, the world's An intra-operative surgical navigation system A non-invasive continuous tissue oxygen A novel technology for reproduction only implantable continuous card
Slide 14: Guardian target problem, benefits and status
For personal use only Target problem Benefits offered Status (Hydrix) • Current standard of care --- patient must • The GUARDIAN, FDA approved, constantly • Exclusive rights licensed have symptoms, recognise the symptoms monitors a heart and alerts patient to see a to distribute in 8 and be able to
Slide 15: Guardian regulatory and reimbursement status by country
Hydrix is actively working on regulatory approvals and reimbursement processes across multiple jurisdictions, and other market development activities to For personal use only commercialise The Guardian Country* / Agency Appl. Date Status Notes USA / FDA n/a Approved Distributed in the USA by Angel M
Slide 16: Guardian market potential
For personal use only GUARDIAN® market Potential Market Size (illustration only) Annual Sales Volume (units) Annual Sales Value (A$)2 penetration leverages ACS Incidences p.a. Region Population (M) 2.0% 5.0% 2.0% 5.0% >5-decades of 1 pacemaker surgery Australia 25.8 75,000 1,500 3,750 $15.0m $37.5m
Slide 17: Disclaimer
For personal use only This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of
Slide 18: www.hydrix.com
For personal use only www.hydrix.com